Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

TY - JOUR

T1 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

AU - Dreyling, M.

AU - Ghielmini, M.

AU - Rule, S.

AU - Salles, G.

AU - Ladetto, M.

AU - Tonino, S. H.

AU - Herfarth, K.

AU - Seymour, J. F.

AU - ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

AU - Jerkeman, M.

N1 - Funding Information: MD has reported scientific advisory boards for Accerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche and Sandoz, speaker's honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research support from Celgene, Janssen, Mundipharma and Roche; GS has reported advisory boards or consulting for AbbVie, Autolus, Celgene, Genmab, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, MorphoSys, Novartis, Roche, Servier and Takeda and educational events with AbbVie, Amgen, Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche, Servier and Takeda; ML has reported consultancy, advisory boards, scientific meetings, institutional research support and contracts from AbbVie, Acerta, Amgen, Archigen, ADC Therapeutics, BeiGene, Celgene, Gilead, J&J, Jazz, Roche, Sandoz and Takeda and has received research grants from Celgene, J&J and BeiGene; KH has received research support from Roche; JFS has reported advisory boards for AbbVie, Celgene, Janssen, Roche, Acerta, Genentech, Gilead, Mei Pharma, MorphoSys, Sunesis and Takeda, speaker's bureau for AbbVie, Celgene and Roche and has received research funding from AbbVie, Celgene, Roche and Janssen; MJ has received research funding from Celgene, Roche, Gilead, AbbVie and Janssen and honoraria from Kite, Kyowa-Kirin and Acerta; MG , SR and SHT have declared no conflicts of interest. Funding Information: The ESMO Guidelines Committee thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. They also thank the European Cancer Patient Coalition and the following patient organisation for their review: the Polish Lymphoma Association Owl Eyes. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. MD has reported scientific advisory boards for Accerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche and Sandoz, speaker's honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research support from Celgene, Janssen, Mundipharma and Roche; GS has reported advisory boards or consulting for AbbVie, Autolus, Celgene, Genmab, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, MorphoSys, Novartis, Roche, Servier and Takeda and educational events with AbbVie, Amgen, Celgene, Gilead, Janssen, Kite, MorphoSys, Novartis, Roche, Servier and Takeda; ML has reported consultancy, advisory boards, scientific meetings, institutional research support and contracts from AbbVie, Acerta, Amgen, Archigen, ADC Therapeutics, BeiGene, Celgene, Gilead, J&J, Jazz, Roche, Sandoz and Takeda and has received research grants from Celgene, J&J and BeiGene; KH has received research support from Roche; JFS has reported advisory boards for AbbVie, Celgene, Janssen, Roche, Acerta, Genentech, Gilead, Mei Pharma, MorphoSys, Sunesis and Takeda, speaker's bureau for AbbVie, Celgene and Roche and has received research funding from AbbVie, Celgene, Roche and Janssen; MJ has received research funding from Celgene, Roche, Gilead, AbbVie and Janssen and honoraria from Kite, Kyowa-Kirin and Acerta; MG, SR and SHT have declared no conflicts of interest. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3/1

Y1 - 2021/3/1

KW - antibody

KW - chemotherapy

KW - follicular lymphoma

KW - lenalidomide

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85102153138&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.annonc.2020.11.008

DO - https://doi.org/10.1016/j.annonc.2020.11.008

M3 - Article

C2 - 33249059

SN - 0923-7534

VL - 32

SP - 298

EP - 308

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -